Status:
ACTIVE_NOT_RECRUITING
Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
Lead Sponsor:
University of Chicago
Conditions:
Kidney Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer. This project asks whether pat...
Eligibility Criteria
Inclusion
- Male and female patients aged 18 years and older.
- Patients must have a solid or cystic renal mass suspicious for malignancy by imaging with ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI).
- Patients must be initially scheduled RALPN as opposed to radical nephrectomy or other techniques for partial nephrectomy such as open surgery or pure laparoscopy without robot assistance.
- Patients with bilateral kidneys or a solitary kidney, so long as these are native kidneys as opposed to a transplanted kidney.
- Patients can have the common single renal artery and single renal vein, or they can have common variants such as two renal arteries and/or two renal veins.
Exclusion
- Patients on hemodialysis.
- Patients who have had a renal transplantation.
- Patients on therapeutic anticoagulation prior to surgery (example anticoagulants include: aspirin 325 mg daily, clopidogrel, warfarin, fondaparinux, dabigatran, and rivaroxaban). However, patients who take aspirin 81 mg daily as their daily regimen will be included.
- Patients with bleeding disorders (example: hemophilia) and other documented coagulopathy (example: chronic liver disease) with INR greater than 1.0 at baseline.
- Patients who have had a prior surgical procedure, aside from percutaneous renal biopsy, on the kidney in the current operation.
- Patients with over 100 mL of estimated blood loss (calculated by anesthesia team using the suction canisters) prior to clamping of the renal hilum will be excluded.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT04120805
Start Date
January 1 2016
End Date
March 1 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637